Replimune(US:REPL) Prnewswire·2025-08-26 12:46Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. due to alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate and not well-controlled by the FDA [2]. - Defendants' statements about Replimune's business, operations, and prospects were claimed to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].